RenovoRx, Inc. (RNXT)
Total Valuation
RenovoRx has a market cap or net worth of $21.88 million. The enterprise value is $18.65 million.
Market Cap | 21.88M |
Enterprise Value | 18.65M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
Earnings Date | May 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 10.69 million shares outstanding. The number of shares has increased by 17.93% in one year.
Shares Outstanding | 10.69M |
Shares Change (YoY) | +17.93% |
Shares Change (QoQ) | +0.36% |
Owned by Insiders (%) | 18.57% |
Owned by Institutions (%) | 3.10% |
Float | 9.43M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3,645.85 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19, with zero debt.
Current Ratio | 2.19 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | 655.36 |
Financial Efficiency
Return on equity (ROE) is -345.30% and return on invested capital (ROIC) is -196,483.33%.
Return on Equity (ROE) | -345.30% |
Return on Assets (ROA) | -169.20% |
Return on Capital (ROIC) | -196,483.33% |
Revenue Per Employee | n/a |
Profits Per Employee | -$916,100 |
Employee Count | 10 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.77% in the last 52 weeks. The beta is 1.12, so RenovoRx's price volatility has been higher than the market average.
Beta (1Y) | 1.12 |
52-Week Price Change | -56.77% |
50-Day Moving Average | 1.44 |
200-Day Moving Average | 1.44 |
Relative Strength Index (RSI) | 42.95 |
Average Volume (30 Days) | 74,116 |
Short Selling Information
The latest short interest is 15,634, so 0.15% of the outstanding shares have been sold short.
Short Interest | 15,634 |
Short Previous Month | 6,835 |
Short % of Shares Out | 0.15% |
Short % of Float | 0.17% |
Short Ratio (days to cover) | 0.12 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -11.79M |
Pretax Income | -9.16M |
Net Income | -9.16M |
EBITDA | -9.18M |
EBIT | -9.18M |
Earnings Per Share (EPS) | -$0.94 |
Balance Sheet
The company has $3.23 million in cash and no debt, giving a net cash position of $3.23 million or $0.30 per share.
Cash & Cash Equivalents | 3.23M |
Total Debt | n/a |
Net Cash | 3.23M |
Net Cash Per Share | $0.30 |
Equity / Book Value | 6,000 |
Book Value Per Share | 0.00 |
Working Capital | 1.91M |
Cash Flow
Operating Cash Flow | -9.89M |
Capital Expenditures | n/a |
Free Cash Flow | -9.89M |
FCF Per Share | -$0.93 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -17.93% |
Shareholder Yield | -17.93% |
Earnings Yield | -41.88% |
FCF Yield | -45.19% |
Analyst Forecast
The average price target for RenovoRx is $4.00, which is 185.71% higher than the current price. The consensus rating is "Buy".
Price Target | $4.00 |
Price Target Difference | 185.71% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |